ConductScience.org, home

Comparison · NCT00964496-87f29d26

Thalidomide Group vs Iron-controlled Group: Participants Dependent on Blood Transfusions

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Thalidomide Group vs Iron-controlled Group: Participants Dependent on Blood Transfusions. Trial comparisons, record NCT00964496-87f29d26. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00964496-87f29d26

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1070.03710.272wilson
Risk in group 20.4810.3070.66wilson
Risk difference, group 1 minus group 2-0.374-0.566-0.135newcombe hybrid score
Risk ratio, group 1 over group 20.2230.07130.695log
Odds ratio, group 1 over group 20.1290.03140.532log
Number needed to treat, for one fewer participant with the outcome on Thalidomide Group than on Iron-controlled Group2.671.777.43from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Thalidomide Groupinterventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)328OG000
Group 2Iron-controlled Groupinterventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)1327OG001

Outcome

Type
SECONDARY
Title
Participants Dependent on Blood Transfusions
Description
Numbers of participants dependent on blood transfusions
Time frame
52 months
Population
55 patients were enrolled in our study. One in iron-controlled group refused to continue for personal reason after 8 months, two other in thalidomide plus iron group refused to take study medications after 4 weeks treatment due to leukopenia and unexplained somnolence. Analysis was performed according to Intention-to-Treat principle.

Source ClinicalTrials.gov

Trial

Title
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
NCT number
NCT00964496
Phases
PHASE2
Conditions
Obscure Gastrointestinal Bleeding, Angiodysplasia, Gastric Antral Vascular Ectasia, Thalidomide
Interventions
Thalidomide, Iron
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Results first posted
2010-04-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00964496-87f29d26